Fibroblasts: The missing link between fibrotic lung diseases of different etiologies?

Respiratory Research

Volumn 14, Issue 1, 2013, Pages

  Crestani, Bruno ^a,b,c,d   Besnard, Valerie ^a,d   Plantier, Laurent ^a,b,c,d   Borensztajn, Keren ^a,d   Mailleux, Arnaud ^a,d  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c BICHAT HOSPITAL   (France)

^d Departement Hospitalo universtaire FIRE Fibrosis Inflammation and Remodeling and LabEx Inflamex   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; FIBRONECTIN; GAMMA INTERFERON; KERATINOCYTE GROWTH FACTOR; MICRORNA; MUCIN 5B; PIRFENIDONE; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SCLEROPROTEIN; CYTOKINE;

CHRONIC RESPIRATORY FAILURE; CLINICAL TRIAL (TOPIC); DEACETYLATION; DNA METHYLATION; DRUG TARGETING; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG FIBROBLAST; LUNG FIBROSIS; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); NOTE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCLERODERMA; ANIMAL; ARTICLE; BIOLOGICAL MODEL; FIBROBLAST; IMMUNOLOGY; LUNG; PATHOLOGY;

ANIMALS; CYTOKINES; FIBROBLASTS; HUMANS; LUNG; MODELS, IMMUNOLOGICAL; PULMONARY FIBROSIS;

EID: 84880902395     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-14-81     Document Type: Note

References (16)

1. Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377(9779):1760-1769. Epub 2011/05/17, 10.1016/S0140-6736(11)60405-4, 21571362.
2. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012, 380(9842):689-698. Epub 2012/08/21, 10.1016/S0140-6736(12)61079-4, 22901890.
3. Peljto AL, Steele MP, Fingerlin TE, Hinchcliff ME, Murphy E, Podlusky S, et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 2012, Epub 2012/05/12.
4. Andersson-Sjoland A, Nihlberg K, Eriksson L, Bjermer L, Westergren-Thorsson G. Fibrocytes and the tissue niche in lung repair. Respir Res 2011, 12:76. Epub 2011/06/11, 10.1186/1465-9921-12-76, 3138446, 21658209.
5. Noble PW, Barkauskas CE, Jiang D. Pulmonary fibrosis: patterns and perpetrators. J Clin Invest 2012, 122(8):2756-62. Epub 2012/08/02, 10.1172/JCI60323, 3408732, 22850886.
6. Marchand-Adam S, Fabre A, Mailleux AA, Marchal J, Quesnel C, Kataoka H, et al. Defect of pro-hepatocyte growth factor activation by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006, 174(1):58-66. Epub 2006/04/01, 10.1164/rccm.200507-1074OC, 16574935.
7. King TE, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011, 378(9807):1949-61. Epub 2011/07/02, 10.1016/S0140-6736(11)60052-4, 21719092.
8. Robinson CM, Neary R, Levendale A, Watson CJ, Baugh JA. Hypoxia-induced DNA hypermethylation in human pulmonary fibroblasts is associated with Thy-1 promoter methylation and the development of a pro-fibrotic phenotype. Respir Res 2012, 13:74. Epub 2012/09/04, 10.1186/1465-9921-13-74, 3519562, 22938014.
9. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Translational Res J Lab Clin Med 2011, 157(4):191-9. Epub 2011/03/23.
10. Lindahl GE, Stock CJW, Shi-We X, Leoni-Garcia P, Sestini PS, Howat S, et al. Microarray profile reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respir Res 2013, in press.
11. Higgs BW, Liu Z, White B, Zhu W, White WI, Morehouse C, et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011, 70(11):2029-36. Epub 2011/08/02, 10.1136/ard.2011.150326, 21803750.
12. Grassegger A, Schuler G, Hessenberger G, Walder-Hantich B, Jabkowski J, MacHeiner W, et al. Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial. Br J Dermatol 1998, 139:639-48. 10.1046/j.1365-2133.1998.02460.x, 9892907.
13. Raghu G, Bozic CR, Brown K, Lynch DA, Center D, Aguayo SM, et al. Feasibility of a trial of interferon-beta1A in the treatment of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 163:A707.
14. King TE, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009, 374(9685):222-8. Epub 2009/07/03, 10.1016/S0140-6736(09)60551-1, 19570573.
15. Diaz KT, Skaria S, Harris K, Solomita M, Lau S, Bauer K, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv 2012, 25(2):79-87. Epub 2012/03/01, 10.1089/jamp.2011.0919, 22360317.
16. Soon WW, Hariharan M, Snyder MP. High-throughput sequencing for biology and medicine. Mol Syst Biol 2013, 9:640. Epub 2013/01/24, 3564260, 23340846.